Celebrating research and collaboration at the 35th International Symposium on ALS/MND
PrimeC was reported as safe and well tolerated in a Phase 2 trial and its open-label extension in people with motor neurone disease (MND). The results also showed promising signs that it may slow disease progression and delay breathing problems for some participants. These findings need testing in a larger Phase 3 trial.
Why this matters
The findings may inform further testing of PrimeC, a combination of ciprofloxacin and celecoxib. They do not yet establish that PrimeC benefits people with MND or change treatment, because the reported results came from Phase 2 testing and still require confirmation in a larger trial.
Limitations and context
This information comes from an organisation’s report of a presentation at the 2024 International Symposium on ALS/MND, not from the primary trial report. The source gives no participant numbers or detailed results, and says the findings require a larger Phase 3 trial.